CoChat
Sign Up
Cited by 634Schizophrenia research and treatmentPituitary Gland Disorders and TreatmentsGrowth Hormone and Insulin-like Growth Factors

The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.

Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management

Haddad, Peter M, Wieck, Angelika·2004·Drugs
DOI 10.2165/00003495-200464200-00003
Open this paper in CoChat — free account

Abstract

Hyperprolactinaemia is an important but neglected adverse effect of antipsychotic medication. It occurs frequently with conventional antipsychotics and some atypical antipsychotics (risperidone and amisulpride) but is rare with other atypical antipsychotics (aripiprazole, clozapine, olanzapine, quetiapine, ziprasidone). For this reason the terms 'prolactin-sparing' and 'prolactin-raising' are more useful than 'atypical' and 'conventional' when considering the effect of antipsychotic drugs on serum prolactin. During antipsychotic treatment prolactin levels can rise 10-fold or more above pretreatment values. In a recent study approximately 60% of women and 40% of men treated with a prolactin-raising antipsychotic had a prolactin level above the upper limit of the normal range. The distinction between asymptomatic and symptomatic hyperprolactinaemia is important but is often not made in the literature. Some symptoms of hyperprolactinaemia result from a direct effect of prolactin on target tissues but others result from hypogonadism caused by prolactin disrupting the normal functioning of the hypothalamic-pituitary-gonadal axis. Symptoms of hyperprolactinaemia include gynaecomastia, galactorrhoea, sexual dysfunction, infertility, oligomenorrhoea and amenorrhoea. These symptoms are little researched in psychiatric patients. Existing data suggest that they are common but that clinicians underestimate their prevalence. For example, well conducted studies of women treated with conventional antipsychotics have reported prevalence rates of approximately 45% for oligomenorrhoea/amenorrhoea and 19% for galactorrhoea. An illness-related under-function of the hypothalamic-pituitary-gonadal axis in female patients with schizophrenia may also contribute to menstrual irregularities. Long-term consequences of antipsychotic-related hypogonadism require further research but are likely and include premature bone loss in men and women. There are conflicting data on whether hyperprolactinaemia is associated with an increased risk of breast cancer in women. In patients prescribed antipsychotics who have biochemically confirmed hyperprolactinaemia it is important to exclude other causes of prolactin elevation, in particular tumours in the hypothalamic-pituitary area. If a patient has been amenorrhoeic for 1 year or more, investigations should include bone mineral density measurements. Management should be tailored to the individual patient. Options include reducing the dose of the antipsychotic, switching to a prolactin-sparing agent, prescribing a dopamine receptor agonist and prescribing estrogen replacement in hypoestrogenic female patients. The efficacy and risks of the last two treatment options have not been systematically examined. Antipsychotic-induced hyperprolactinaemia should become a focus of interest in the drug treatment of psychiatric patients, particularly given the recent introduction of prolactin-sparing antipsychotics. Appropriate investigations and effective management should reduce the burden of adverse effects and prevent long-term consequences.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003495-200464200-00003

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 145 references

Research works printed but not linked: 18

  1. Hellewell, 1998, Eur Neuropsychopharmacol, 8, S248
  2. Marken, 1992, Clin Pharm, 11, 851
  3. Tuomisto, 1985, Pharmacol Rev, 37, 249
  4. Oseko, 1988, Obstet Gynecol, 72, 267
  5. Kuruvilla, 1992, Clin Exp Pharmacol Physiol, 19, 603, 10.1111/j.1440-1681.1992.tb00511.x · DOI
  6. Turkington, 1972, Arch Intern Med, 130, 349, 10.1001/archinte.1972.03650030031008 · DOI
  7. Kaneda, 2000, Neuroendocrinol Lett, 21, 447
  8. Peters, 1986, Obstet Gynecol, 67, 82
  9. Biller, 1992, J Clin Endocrinol Metab, 75, 692
  10. Peris, 1992, Alcohol Alcohol, 27, 619
  11. Welsch, 1977, Cancer Res, 37, 951
  12. Pearson, 1969, Trans Assoc Am Physicians, 82, 225
  13. Kanhouwa, 1984, J Natl Med Assoc, 76, 785
  14. Cheung, 2001, Obstet Gynecol, 98, 325
  15. Matsuoka, 1986, Jpn J Psychiatry Neurol, 40, 639
  16. Smith, 1992, J Reprod Med, 37, 737
  17. Perovitch, 1989, J Clin Psychopharmacol, 9, 417
  18. Molitch, 2000, Endocr Pract, 6, 479

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Haddad, P. M., & Wieck, A.
Affiliations
University of Manchester (GB)
ORCID
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2004
Volume
64
Issue
20
Pages
2291-2314
ISSN
0012-6667 (ISSN-L)
DOI
10.2165/00003495-200464200-00003
OpenAlex
W2032902988
Cited by
634
References
145
Citations by year
2026: 21 · 2025: 26 · 2024: 19 · 2023: 20 · 2022: 30 · 2021: 17 · 2020: 23 · 2019: 23 · 2018: 18 · 2017: 23 · 2016: 34 · 2015: 32 · 2014: 24 · 2013: 33 · 2012: 32
FWCI
4.15
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
prolactin, atypical antipsychotics, typical antipsychotics, hypogonadism, hypothalamic-pituitary-gonadal axis, galactorrhea, amenorrhea, oligomenorrhea, gynecomastia, sexual dysfunction, infertility, bone loss, breast cancer risk
MeSH terms
Adolescent, Adult, Child, Child, Preschool, Female, Humans, Hyperprolactinemia, Male, Prolactin, Schizophrenia, Antipsychotic Agents, Bone Density, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review